Richard Buller, VP at Pfizer, to Give a Keynote at GTCbio’s Biomarker Summit Europe 2016

Berlin, Germany, July 10, 2016 --(PR.com)-- Richard E. Buller, Vice President of Oncology, Clinical Development & Head of Global Product Development at Pfizer will give a keynote presentation on, "Feedback Loops Between Biomarkers and Targeted Agents in Clinical Trials and Beyond: Lessons from Anaplastic Lymphoma Kinase (ALK+) Driven Non-Small Cell Lung Cancer (NSCLC)" at GTCbio’s Biomarker Summit Europe 2016 to be held on October 5-7, 2016 in Berlin, Germany.

Utilizing public data from the development of multiple ALK inhibitors and the performance characteristics of multiple diagnostic tests for disease relevant biomarkers, Richard Buller will discuss how opportunities for the advancement of regulatory science have evolved and come to fruition in both the drug and diagnostic spaces.

The summit will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, companion diagnostics, the health economics value of biomarkers, reimbursement environment, and perspective on cell free biomarkers for disease diagnostics. Scientific data, case studies and discussions will be facilitated by key representatives from pharma, biotech, academia and the public sector.

Biomarker Summit Europe 2016 consists of four conferences:

10th Biomarkers in Drug Discovery & Development
I. Biomarker Discovery & Identification Strategies
II. Biomarkers from Qualification to Validation
III. Biomarkers of Translational Medicine: Safety, PK/PD, & Efficacy
IV. Biomarkers in Personalized Medicine
V. Big Data Analytics for Biomarkers Development

5th Biomarkers in Diagnostics
I. Novel Diagnostic Technologies
II. New Diagnostic Biomarkers & Their Development
III. Companion Diagnostics Development & Commercialization
IV. Joint Session: Clinical Utility of Diagnostic & Screening Biomarkers
V. Joint Session: Health Economics Value of Biomarkers & Reimbursement Environment
VI. Joint Session: Regulatory Considerations in Clinical Dx

Biomarkers in Clinical Development & Clinical Trials
I. Joint Session: Clinical Utility of Diagnostic & Screening Biomarkers
II. Joint Session: Health Economics Value of Biomarkers & Reimbursement Environment
III. Joint Session: Regulatory Considerations in Clinical Dx
IV. Clinical Trials & Developments
V. Biomarkers & Surrogate Endpoints for Clinical Trials

Cell-Free Biomarkers
I. Circulating Biomarkers Overview
II. Cell-free DNA & RNA Technologies & Their Platforms
III. Clinical Applications of Cell-Free DNA & RNA in Disease Diagnosis & Management
IV. New Developments in Cell-Free Biomarkers
V. Exosomes in Diagnosis, Treatment, & Disease Management

For more information, please visit the website: www.gtcbio.com/conferences/biomarker-summit-europe-overview

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433